New Point-of-Care Test Measures Response to Clopidogrel

 

December 30, 2009

December 30, 2009 – Medical device company Emerging Healthcare Solutions LLC (EHS) entered into an agreement to distribute ThromboVision’s T-Guide, a new diagnostic test to assess patient response to clopidogrel.

The option agreement gives the companies a mutual due diligence review period prior to completing an investment and profit sharing agreement.

More than 50 million Americans take aspirin and the anti-platelet drug Plavix (clopidogrel) to prevent heart attacks and strokes. Up to 30 percent of these patients may not respond to Plavix. ThromboVision’s T-Guide provides a simple, inexpensive, point-of-care diagnostic test that can show a patient’s responsiveness to the drug.

EHS is actively acquiring licensing and/or distribution agreements for the North American market.

For more information: www.thrombovision.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.